(b)(4).During processing of this complaint, attempts were made to obtain complete event, patient and device information.There was no reported device malfunction and the product was not returned.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.The reported patient effect of angina is listed in the xience prime everolimus eluting coronary stent systems instructions for use as a known patient effect of coronary stenting procedures.A conclusive cause for the reported patient effects and the relationship to the product, if any, cannot be determined and there is no indication of a product quality issue with respect to manufacture, design or labeling.
|
It was reported that on (b)(6) 2014 the 3.5x28 mm xience prime stent was implanted in the distal circumflex coronary artery and the 4.0x23 mm xience prime stent was implanted in the proximal cx artery.In (b)(6) 2015, the patient had intermittent chest tightness, shortness of breath, sweating, headache, and dizziness.The patient was re-admitted to the hospital on (b)(6) 2016.This was classified as unstable angina.Medication was given intravenously and the condition resolved on (b)(6) 2016.The patient was discharged.No additional information was provided.
|